NasdaqGS - Delayed Quote USD

Sinovac Biotech Ltd. (SVA)

6.47

0.00

(0.00%)

As of April 4 at 4:00 PM EDT. Market Open.

Sinovac Amends Shareholder Rights Plan

BEIJING, February 21, 2024--Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2024 to February 22, 2025.

Business Wire last month

SVA
0.00%
Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer

BEIJING, January 18, 2024--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that its Board of Directors (the "Board of Directors") unanimously determined that the partial tender offer (the "Tender Offer") by Alternative Liquidity Index LP ("Alternative Liquidity") to acquire up to 10,000,000 common shares of Sinovac (the "Shares") for $0.03 per share in cash (the "Offer Price") is NOT advisable and is NOT

Business Wire 2 months ago

SVA
0.00%
SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection

BEIJING, September 11, 2023--Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection ("SA55 Injection") in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently.

Business Wire 7 months ago

SVA
0.00%
Sinovac Confirms Receipt of an Unsolicited Partial Tender Offer

BEIJING, August 29, 2023--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, confirmed today that it is aware of an unsolicited partial tender offer from Alternative Liquidity Index LP to purchase up to a maximum of 10,000,000 shares of the Company, representing approximately 10.05% of the Company’s outstanding shares, for $0.03 per share in cash.

Business Wire 7 months ago

SVA
0.00%
Sinovac Announces Change of Legal Representative of Sinovac Beijing

BEIJING, August 28, 2023--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that the Company’s subsidiary, Sinovac Biotech Co., Ltd. ("Sinovac Beijing"), has changed its legal representative to Mr. Weidong Yin, the Company’s Chairman, President and Chief Executive Officer.

Business Wire 7 months ago

SVA
0.00%
SINOVAC Reports Unaudited First Half of 2023 Financial Results

BEIJING, August 15, 2023--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2023.

Business Wire 8 months ago

SVA
0.00%
SINOVAC’s CoronaVac® Answers Hong Kong’s Need for Self-Pay COVID-19 Vaccines

HONG KONG, May 10, 2023--Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced it will provide its inactivated COVID-19 vaccine, CoronaVac® (original strains), to self-paying groups in Hong Kong. Additionally, the company will collaborate with local charity groups to provide donations, giving more children in Hong Kong access to free vaccines to protect against COVID-19.

Business Wire 11 months ago

SVA
0.00%
SINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-F

BEIJING, May 01, 2023--SINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-F

Business Wire 11 months ago

SVA
0.00%

Performance Overview

Return	SVA	S&P 500
YTD	0.00%	+4.09%
1-Year	0.00%	+19.49%
3-Year	0.00%	+18.62%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sinovac Biotech Ltd. (SVA)

Sinovac Amends Shareholder Rights Plan

Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer

SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection

Sinovac Confirms Receipt of an Unsolicited Partial Tender Offer

Sinovac Announces Change of Legal Representative of Sinovac Beijing

SINOVAC Reports Unaudited First Half of 2023 Financial Results

SINOVAC’s CoronaVac® Answers Hong Kong’s Need for Self-Pay COVID-19 Vaccines

SINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-F

Performance Overview